150 related articles for article (PubMed ID: 14973413)
1. [Biologic therapy and epithelial ovarian cancer].
Porpiglia M; Vicelli R; Durando A; Fracchioli S; Puopolo M; Katsaros D; Bellino R; Benedetto C
Minerva Ginecol; 2004 Feb; 56(1):91-104. PubMed ID: 14973413
[TBL] [Abstract][Full Text] [Related]
2. [Gene therapy and ovarian cancer: update of clinical trials].
Collinet P; Lanvin D; Vereecque R; Quesnel B; Querleu D
J Gynecol Obstet Biol Reprod (Paris); 2000 Oct; 29(6):532-7. PubMed ID: 11084459
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
4. From gene therapy to virotherapy for ovarian cancer.
Stoff-Khalili MA; Dall P; Curiel DT
Minerva Ginecol; 2004 Dec; 56(6):503-14. PubMed ID: 15729203
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for ovarian cancer (review).
Wolf JK; Jenkins AD
Int J Oncol; 2002 Sep; 21(3):461-8. PubMed ID: 12168087
[TBL] [Abstract][Full Text] [Related]
6. Biological therapy of ovarian cancer: current directions.
Bookman MA
Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851
[TBL] [Abstract][Full Text] [Related]
7. Vaccination as a treatment for breast or ovarian cancer.
Holmberg LA; Sandmaier B
Expert Rev Vaccines; 2004 Jun; 3(3):269-77. PubMed ID: 15176943
[TBL] [Abstract][Full Text] [Related]
8. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy for breast cancer].
Takeda Y; Eriguchi M
Nihon Rinsho; 2001 Jan; 59(1):110-8. PubMed ID: 11197840
[TBL] [Abstract][Full Text] [Related]
10. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
11. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy of ovarian cancer.
Bauknecht T; Meinhold-Heerlein I
Curr Womens Health Rep; 2002 Feb; 2(1):39-46. PubMed ID: 12112982
[TBL] [Abstract][Full Text] [Related]
13. [Gene therapy of breast cancer].
Takeda Y; Tahara H
Nihon Rinsho; 2000 Apr; 58 Suppl():366-73. PubMed ID: 11026020
[No Abstract] [Full Text] [Related]
14. Novel therapeutic agents in ovarian cancer.
Agarwal R; Linch M; Kaye SB
Eur J Surg Oncol; 2006 Oct; 32(8):875-86. PubMed ID: 16704916
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional targeting for ovarian cancer gene therapy.
Casado E; Nettelbeck DM; Gomez-Navarro J; Hemminki A; Gonzalez Baron M; Siegal GP; Barnes MN; Alvarez RD; Curiel DT
Gynecol Oncol; 2001 Aug; 82(2):229-37. PubMed ID: 11531272
[TBL] [Abstract][Full Text] [Related]
16. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Weberpals JI; Clark-Knowles KV; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(19):3259-67. PubMed ID: 18591560
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for ovarian carcinoma.
Robertson MW; Barnes MN; Rancourt C; Wang M; Grim J; Alvarez RD; Siegal GP; Curiel DT
Semin Oncol; 1998 Jun; 25(3):397-406. PubMed ID: 9633852
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
Malacrida S; Agata S; Callegaro M; Casella C; Barana D; Scaini MC; Manoukian S; Oliani C; Radice P; Barile M; Menin C; D'Andrea E; Montagna M
J Clin Oncol; 2008 Jan; 26(1):26-31. PubMed ID: 18165637
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-based clinical trials in ovarian cancer.
Leffers N; Daemen T; Boezen HM; Melief KJ; Nijman HW
Expert Rev Vaccines; 2011 Jun; 10(6):775-84. PubMed ID: 21692699
[TBL] [Abstract][Full Text] [Related]
20. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
